NON-PROFIT ORG. U.S. POSTAGE
PAID
NEW HAVEN, CT
333 Cedar Street PO Box 208058 New Haven, CT 06520-8058
Hematology Program at Smilow Cancer Hospital 35 Park Street New Haven, CT 06511 203-200-4363 smilowcancerhospital.org
PERMIT #526
Hematologist, Dr. Cristian C. Taborda, Joins Smilow Cancer Hospital Cristian C. Taborda, MD
Assistant Professor of Medicine (Medical Oncology and Hematology) Appointments: 203-200-4363 Email: cristian.taborda@yale.edu
Cristian C. Taborda, MD, is an assistant professor of medicine (medical oncology and hematology). He cares for patients with lymphoma as part of the Hematology Program at Smilow Cancer Hospital in New Haven and North Haven. He also cares for patients who are undergoing stem cell transplantation or cellular therapies. He received his medical degree from Columbia University Vagelos College of Physicians and Surgeons and completed residency training in Internal Medicine at the University of Pennsylvania. He then trained in the Yale Medical Oncology-Hematology Fellowship Program, where he developed a clinical and academic focus on lymphoid disorders, stem cell transplantation, and cellular therapies. Dr. Taborda’s research focuses on improving outcomes for patients with aggressive lymphoid malignancies,
Locations:
Smilow Cancer Hospital 35 Park Street, seventh floor New Haven, CT 06511 Smilow Cancer Hospital at North Haven 6 Devine Street North Haven, CT 06473
particularly T-cell lymphomas and acute lymphoblastic leukemia (ALL). He has led studies examining longterm outcomes after allogeneic stem cell transplantation for T-cell lymphomas and national database analyses of treatment and survival among older adults with ALL. He has also led prospective initiatives using artificial intelligence to improve clinical trial enrollment in hematologic malignancies. His current work focuses on developing and expanding clinical trials in lymphoid cancers while designing strategies to improve trial access and participation, particularly for older adults. His work aims to ensure that advances in immunotherapy and cellular therapy are delivered safely and equitably to an increasingly diverse older patient population.